Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Exenatide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Vivani Medical Gets Regulatory Clearance for GLP-1 Implant Trial in Obese Patients
Details : NPM115 (exenatide) implant i is being evaluated in the early-stage clinical trial studies for the treatment of obesity and Type 2 diabetes.
Brand Name : NPM115
Molecule Type : Peptide
Upfront Cash : Not Applicable
September 26, 2024
Lead Product(s) : Exenatide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Exenatide
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Vivani Medical Announces Positive Preclinical Results with GLP-1 Liver Implant
Details : NPM-119 (exenatide) is a GLP-1 agonist miniature long-term subdermal implant, which is currently being evaluated for the treatment of patients with type-2 diabetes.
Brand Name : NPM-115
Molecule Type : Peptide
Upfront Cash : Not Applicable
September 04, 2024
Lead Product(s) : Exenatide
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Exenatide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Vivani Medical Updates on NPM-115 GLP-1 Obesity Implant Program Development
Details : NPM-115 (exenatide implant) is a GLP-1R (Glucagon-like peptide 1 receptor) agonists, peptide drug, which is being evaluated for the chronic weight management in obesity patients.
Brand Name : NPM-115
Molecule Type : Peptide
Upfront Cash : Not Applicable
July 11, 2024
Lead Product(s) : Exenatide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Exenatide
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Clears Vivani's IND for NPM-119 Drug Implant
Details : NPM-119 (exenatide) is a GLP-1 agonist miniature long-term subdermal implant, which is currently being evaluated for the treatment of patients with type-2 diabetes.
Brand Name : NPM-115
Molecule Type : Peptide
Upfront Cash : Not Applicable
June 13, 2024
Lead Product(s) : Exenatide
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Exenatide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Vivani Medical Reports Positive NPM-115 Weight Loss Data Comparable to Ozempic®/Wegovy®
Details : NPM-115 (exenatide implant) is a GLP-1R (Glucagon-like peptide 1 receptor) agonists, peptide drug, which is being evaluated for the chronic weight management in obesity patients.
Brand Name : NPM-115
Molecule Type : Peptide
Upfront Cash : Not Applicable
February 28, 2024
Lead Product(s) : Exenatide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Neuraly Announces Topline Results from Phase 2 Trial of NLY01 in Parkinson's Disease
Details : NLY01 is a proprietary long-acting analogue of exendin-4, a glucagon-like peptide-1 receptor (GLP-1R) agonist that slows progression in animal models of parkinson’s and alzheimer’s disease.
Brand Name : NLY01
Molecule Type : Peptide
Upfront Cash : Not Applicable
March 27, 2023
Lead Product(s) : Exenatide
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Sponsor : Second Sight Medical Products
Deal Size : Undisclosed
Deal Type : Merger
Details : Upon completion of the merger, the Company has to advance the development of Vivani’s portfolio, which includes lead asset NPM-119 (exenatide implant), into clinical-stage development for the treatment of patients with Type 2 diabetes.
Brand Name : NPM-119
Molecule Type : Peptide
Upfront Cash : $55.0 million
August 30, 2022
Lead Product(s) : Exenatide
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Sponsor : Second Sight Medical Products
Deal Size : Undisclosed
Deal Type : Merger
Lead Product(s) : Exenatide
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Sponsor : Nano Precision Medical
Deal Size : Undisclosed
Deal Type : Merger
Details : Nano Precision Medical, leveraging its proprietary NanoPortalTM drug implant technology, is creating a portfolio of new drugs including NPM’s lead program, NPM-119, that address medication non-adherence, a leading reason for poor clinical outcomes.
Brand Name : NPM-119
Molecule Type : Peptide
Upfront Cash : Undisclosed
February 07, 2022
Lead Product(s) : Exenatide
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Sponsor : Nano Precision Medical
Deal Size : Undisclosed
Deal Type : Merger
Lead Product(s) : Exenatide
Therapeutic Area : Endocrinology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : BYDUREON BCise brings an important new therapeutic option to physicians caring for children with this chronic disease that can lead to serious long-term issues if not adequately treated.
Brand Name : Bydureon
Molecule Type : Peptide
Upfront Cash : Not Applicable
July 23, 2021
Lead Product(s) : Exenatide
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Exenatide
Therapeutic Area : Endocrinology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Data at week 24 also showed that exenatide once weekly was generally well tolerated and consistent with the existing safety profile in adults. Phase III trial met primary endpoint, significantly reducing blood sugar (HbA1c) versus placebo.
Brand Name : Bydureon
Molecule Type : Peptide
Upfront Cash : Not Applicable
June 25, 2021
Lead Product(s) : Exenatide
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?